Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer

Premier sponsorship of the HERmedicine and OncoMenopause Consortium^® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer

The program addresses non-hormonal approaches to women’s sexual health which aligns with Daré Bioscience's innovation strategy and development of proprietary Sildenafil Cream, 3.6%

Daré Bioscience will also present research on Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Society's 2026 Annual Meeting

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced its premier sponsorship of Managing Menopause After Breast Cancer, a continuing medical education (CME) program presented by HERmedicine and the OncoMenopause Consortium^®. The program will take place October 20, 2026, in San Diego, California, ahead of The Menopause Society's Annual Meeting. The sponsorship supports clinician education and discussion of treatment approaches for women whose options for managing menopausal symptoms, contraception, and sexual health conditions may be limited by a history of breast cancer.

“For women navigating life after breast cancer, this need can be particularly profound. While advances in cancer care have improved outcomes for many patients, survivors may continue to face significant challenges related to menopause, sexual function, intimacy, and overall quality of life. For some women, a history of hormone-sensitive cancer can further complicate treatment decisions, underscoring the importance of advancing research into nonhormonal approaches. Events like this are important for raising awareness of these challenges and advancing conversations around the unmet needs in women’s health. I am pleased to be speaking at this event and contributing to these important discussions,” said Sharon J. Parish, MD, IF, NCMP, Professor of Medicine in Clinical Psychiatry and Professor of Clinical Medicine at Weill Cornell Medical College and Director of Medical Services at New York Presbyterian Hospital/ Westchester Division.

“Surviving breast cancer should not mean having to accept a diminished quality of life or abandon an important part of what makes many women feel whole,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. “Women's menopause and sexual health concerns have too often been overlooked or undertreated, including the particular concerns of breast cancer survivors. By supporting clinicians and researchers advancing the conversation around menopause after breast cancer, we are reinforcing our commitment to ensuring women's sexual health and quality of life are recognized as essential components of healthcare.”

Daré Bioscience's investigational proprietary Sildenafil Cream, 3.6% is just one example of the Company's research into nonhormonal approaches for women's sexual health. Sildenafil acts through a nonhormonal mechanism involving blood flow, which may be relevant to aspects of female sexual function.

For women experiencing sexual health challenges following breast cancer treatment, the development of additional nonhormonal options may be relevant. However, the appropriateness of any treatment must be evaluated based on an individual woman's medical history, symptoms, and clinical circumstances.

“Nonhormonal innovation is important because there is no single treatment approach that meets every woman's needs,” continued Ms. Johnson. “We are advancing science-based solutions across contraception, menopause, sexual health, and other areas of unmet need, including for women who have historically had limited options.”

The Managing Menopause After Breast Cancer program will bring together women's health clinicians to examine the complex clinical considerations involved in managing menopause following breast cancer, including hormonal and nonhormonal treatment approaches, sexual health, and quality of life.

The program will be led by two recognized leaders in women's health and oncology:

• Lisa Larkin, MD, FACP, MSCP, Founder and Executive Director of HERmedicine and the OncoMenopause Consortium®
• Maryam Lustberg, MD, MPH, Director of the Yale Breast Center and Division Chief of Breast Oncology at Yale University School of Medicine

In addition to its sponsorship of the HERmedicine and OncoMenopause Consortium program, Daré Bioscience will participate in The Menopause Society's 2026 Annual Meeting, being held October 20–24, 2026, including a planned scientific poster presentation on data from a Phase 1 clinical study of Sildenafil Cream, 3.6% in postmenopausal women.

For more information about the Managing Menopause After Breast Cancer program, visit https://www.oncomenopause.org/managing-menopause-after-breast-cancer.

HERmedicine is a national 501(c)(3) nonprofit education organization committed to advancing evidence-based women’s health through free live education, clinician and consumer learning, multidisciplinary collaboration, and the practical translation of evidence into care. OncoMenopause™ is HERmedicine’s permanent national education initiative focused on cancer survivorship, menopause, and midlife women’s health. The OncoMenopause Consortium^® is the collaborative multidisciplinary professional community through which the OncoMenopause initiative is advanced. The OncoMenopause Consortium brings clinicians, educators, researchers, advocates, and other leaders together to improve the care of women affected by cancer.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: Daré Bioscience’s product pipeline and portfolio; potential therapeutic benefits for women of Sildenafil Cream, 3.6%, if approved; and potential for Daré Bioscience to bring to market nonhormonal solutions for managing menopause, contraception or women’s sexual health.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Daré Bioscience's ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; dependence on grants and other financial awards from governmental entities and a private foundation and the risk that funding may be reduced, delayed, or terminated; potential suspension and delisting of Daré Bioscience's common stock from The Nasdaq Capital Market; failure or delay in commencing, conducting or completing clinical trials and the inherent uncertainty of outcomes of clinical trials; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; Daré Bioscience's ability to develop, obtain U.S. Food and Drug Administration (FDA) or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; the risk that Daré Bioscience's product candidates may fail to demonstrate acceptable safety and tolerability or sufficient efficacy in clinical trials; Daré Bioscience's dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the potential that a product candidate in clinical development may never advance into or through a pivotal clinical study or obtain FDA or foreign regulatory approval; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré Bioscience's interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré Bioscience anticipates; the risk that the FDA’s 505(b)(2) pathway may not be available for a product candidate as Daré Bioscience anticipates; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré Bioscience's products or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Daré Bioscience’s reliance on Section 503B-registered outsourcing facilities and other third parties to bring DARE to PLAY™ Sildenafil Cream and other solutions to market as compounded drugs or as consumer health products and facilitate access to such products and the risk that those third parties do not perform as expected; difficulties in establishing and sustaining relationships with third-party collaborators; the risk that the FDA could stop permitting Section 503B-registered outsourcing facilities to compound the drug substances in the proprietary formulations Daré Bioscience intends to bring or brings to market or changes the conditions under which those drug substances may be used in compounding or the compounded products may be distributed; the ability of outsourcing facilities for Daré Bioscience’s compounded products to maintain their registration with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act; the timing of establishing, and ability to maintain, state-required licensure or registration to enable fulfillment of prescriptions for DARE to PLAY™ Sildenafil Cream and other solutions brought to market via the Section 503B pathway; Daré Bioscience’s inexperience, as a company, in and limited infrastructure for commercializing products; the degree of market demand and acceptance for the products Daré Bioscience brings to market; competitive product launches; greater than expected costs to bring compounded drug products to market and marketing costs; shifts in consumer spending or behavior; the risk that developments by competitors make Daré Bioscience's products or product candidates less competitive or obsolete; Daré Bioscience's ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience's ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience's ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience's product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience's products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience's ability to raise additional capital or on Daré Bioscience's operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Daré Bioscience's technology systems and/or significantly disrupt Daré Bioscience's business or those of third parties on which Daré Bioscience relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com

Source: Daré Bioscience, Inc.